- Home
- NGS vs CABA Comparison
NGS vs CABA Comparison
Compare NGS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGS
- CABA
- Stock Information
- Founded
- NGS 1998
- CABA 2017
- Country
- NGS United States
- CABA United States
- Employees
- NGS N/A
- CABA N/A
- Industry
- NGS Oilfield Services/Equipment
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NGS Energy
- CABA Health Care
- Exchange
- NGS Nasdaq
- CABA Nasdaq
- Market Cap
- NGS 241.7M
- CABA 110.5M
- IPO Year
- NGS 2002
- CABA 2019
- Fundamental
- Price
- NGS $27.73
- CABA $2.40
- Analyst Decision
- NGS Strong Buy
- CABA Strong Buy
- Analyst Count
- NGS 2
- CABA 9
- Target Price
- NGS $26.50
- CABA $27.22
- AVG Volume (30 Days)
- NGS 78.0K
- CABA 1.8M
- Earning Date
- NGS 11-14-2024
- CABA 11-14-2024
- Dividend Yield
- NGS N/A
- CABA N/A
- EPS Growth
- NGS 605.21
- CABA N/A
- EPS
- NGS 1.28
- CABA N/A
- Revenue
- NGS $152,305,000.00
- CABA N/A
- Revenue This Year
- NGS $30.81
- CABA N/A
- Revenue Next Year
- NGS $13.48
- CABA N/A
- P/E Ratio
- NGS $21.65
- CABA N/A
- Revenue Growth
- NGS 41.72
- CABA N/A
- 52 Week Low
- NGS $13.70
- CABA $1.76
- 52 Week High
- NGS $28.50
- CABA $26.35
- Technical
- Relative Strength Index (RSI)
- NGS 61.67
- CABA 41.85
- Support Level
- NGS $25.17
- CABA $2.14
- Resistance Level
- NGS $26.08
- CABA $2.56
- Average True Range (ATR)
- NGS 1.27
- CABA 0.23
- MACD
- NGS 0.14
- CABA 0.01
- Stochastic Oscillator
- NGS 89.49
- CABA 30.95
About NGS Natural Gas Services Group Inc.
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.